scholarly journals T Cells Can Induce Somatic Mutation in B Cell Receptor-Engaged BL2 Burkitt’s Lymphoma Cells Independently of CD40-CD40 Ligand Interactions

2000 ◽  
Vol 164 (3) ◽  
pp. 1306-1313 ◽  
Author(s):  
Stéphane Denépoux ◽  
Nathalie Fournier ◽  
Catherine Péronne ◽  
Jacques Banchereau ◽  
Serge Lebecque
Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3516-3516
Author(s):  
Moritz Bewarder ◽  
Klaus-Dieter Preuss ◽  
Natalie Fadle ◽  
Evi Regitz ◽  
Lorenz Thurner ◽  
...  

Abstract Background Autoantigens are suspected to play an important role in the pathogenesis of different types of B cell neoplasia. Suggestive of this hypothesis is the restricted usage of a stereotyped IgHv repertoire in CLL, MCL and DLBCL. Further evidence supporting this notion is the identification of specific autoantigens as the target of the B-cell receptor from malignant lymphomas and myelomas, such as paratarg-7 as antigenic target for 15% of paraproteins of MGUS and MM patients. ARS2 was previously identified as the autoantigenic target for the B-cell receptor of approximately 25% of DLBCLs of the ABC type, here termed ARS2 reactive lymphomas. We had recently shown that the B-cell receptor antigens can be used to target B-cell lymphoma cells in vitro and in vivo in an approach designated as BARs (B-cell receptor antigens for reverse targeting), the first therapeutic strategy in oncology with absolute and exclusive specificity for the malignant clone. To test whether BARs can substitute the B-cell binding antibody (e.g. CD19) in T-cell engaging bispecific antibodies, we designed a bispecific CD3/BAR product consisting of a recombinant single chain fragment (scFv) against CD3 linked to ARS2 (CD3-ARS2). One arm of this construct should engage the T cell co-receptor CD3 of human T cells, and the other site should bind to the B cell receptor of ARS2 reactive lymphomas thus specifically redirecting and activating T cells against lymphoma cells. Material and methods VL and VH genes of the CD3 - OKT3 hybridoma and the DNA sequence of the 33 amino acids containing the B-cell receptor binding epitope of ARS2 were cloned into a pcDNA 3.1 vector by standard cloning techniques. VH and VL were linked by a glycine-serine linker, as was VL to the ARS2 epitope resulting in VH-(Gly₄Ser₁)ⁿ-VL-(Gly₄Ser₁)ⁿ-ARS2 peptide chain. The final cloning product was transfected in HEK cells for production of the bispecific construct. Binding capacity to lymphoma cell lines (OCI-Ly3, U2932, HBL-1) and PBMCs was assessed by flow cytometry. Western blot analysis was used for detection of CD3-ARS2 after incubation with the monoclonal anti-His Tag antibody. Cytotoxicity was evaluated by LDH release assay. Results The CD3 - ARS2 bispecific construct bound to CD3 on T cells and the B-cell receptor of ARS2 reactive lymphoma cells. CD3/ARS2 induced rapid cytotoxicity exclusively in ARS2 reactive lymphoma cell lines at concentrations as low as 250 ng/ml with an effector - target ratio of 10:1. Specific T-cell mediated cytotoxicity reached 40% after 4 hours. Lymphoma cell lines with BCRs of a specificity other than ARS2 were not affected. Conclusion The CD3/BAR construct is a novel therapeutic principle for the treatment of B-cell lymphomas, suggesting that BARs might also be useful as part of CAR-T cells. Compared to CD3/CD19 bispecific antibodies the CD3/BARs are exclusively cytotoxic against the malignant clone and spare normal B-cells. This should considerably reduce the acute toxicity of T-cell engaging bispecific constructs and circumvent long-term B cell depletion. Experiments comparing the cytotoxic capacity of CD3/BARs with CD3/CD19 bispecific antibodies are underway, as are analyses evaluating possible synergisms of these constructs. Disclosures No relevant conflicts of interest to declare.


Leukemia ◽  
2010 ◽  
Vol 24 (6) ◽  
pp. 1186-1196 ◽  
Author(s):  
V J Craig ◽  
S B Cogliatti ◽  
I Arnold ◽  
C Gerke ◽  
J-E Balandat ◽  
...  

2004 ◽  
Vol 28 (11) ◽  
pp. 1197-1202 ◽  
Author(s):  
Michelle J. Holder ◽  
Anita Chamba ◽  
Debbie L. Hardie ◽  
Julie P. Deans ◽  
John Gordon

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4143-4143
Author(s):  
Marvyn T. Koning ◽  
Sander A.J. van der Zeeuw ◽  
Marcelo Navarrete ◽  
Cornelis A.M. van Bergen ◽  
Valeri Nteleah ◽  
...  

Abstract Peptides of the B-cell receptor (BCR) may be presented in HLA molecules and therefore be recognized as epitopes by T cells. Bioinformatic evidence indicates that follicular lymphoma cells are selected against expression of a clonal BCR with a high cumulative predicted binding of BCR-derived peptides to the respective patient's HLA complex (Strothmeyer, Blood 2010). This observation suggests T-cell-mediated immunosurveillance against outgrowth of follicular lymphoma cells according to BCR HLA binding strength. Here, we investigate whether this phenomenon pertains to peripheral B cells in 6 healthy donors: 2 donors homozygous for HLA A01*01 / B08*01, 2 homozygous for HLA A02*01 / B7*02, and 2 donors heterozygous for these alleles. Unbiased representation of full-length V(D)J sequences was considered essential for correct data interpretation. PCR primers annealing to conserved motifs of BCR variable regions (e.g. BIOMED-2 protocol) fail to amplify a fraction of BCR, particularly those modified by somatic hypermutation. Therefore, we developed an improved anchored PCR strategy: cDNA was synthesized from poly(A)-RNA from peripheral blood with primers that anneal to specific Ig constant regions. In the same reaction, the 3' cDNA end is extended by switching to an oligonucleotide template containing an anchor sequence (SMART technology; Clontech). Anchor-tagged cDNA was amplified with a primer annealing to the anchor in combination with a nested constant region-specific reverse primer. Dumbbell adapters were added to the termini of 250 ng of purified PCR products. Circular consensus sequencing of single molecules was performed on the PacBio platform (Pacific Biosciences). Using one SMRT PacBio cell per amplicon, separate sequence libraries were created for μ, γ, κ, and λ BCR transcripts. Sequences covered by at least five reads were selected with SMRT Portal software to obtain >95% of sequences without sequence errors as demonstrated on multiple B-cell lines. Selected sequences were analysed by HighV-QUEST software (Alamyar, Immunome Research 2012). After exclusion of non-BCR sequences and duplicate BCR transcripts, a median of 5318 (range: 670-8752) individual BCR sequences was obtained per library. Binding affinity of nonamers in in-silico-translated BCR were calculated for the 4 HLA alleles by the NetMHC 3.4 algorithm. The fractions of BCR lacking any weak HLA binding peptide (NetMHC IC50 <500nM) within a library were compared between donors positive or negative for any HLA molecule. μ VDJ transcripts without HLA binding peptides were significantly more frequent for all HLA alleles in donors that actually express that particular allele (Table). With the exception of HLA A01*01, similar results were observed for γ transcripts. While the fraction of κ VJ transcripts without an HLA binder was overall higher in HLA A01*01 and B08*01, HLA-positive individuals had higher proportions of non-HLA binding sequences. λ transcripts were less likely to contain HLA binders with respect to HLA B07*02 and B08*01 but not to the HLA A alleles. Analogous analyses were performed for CDR3 regions as annotated by HighV-QUEST plus six amino acids on either flank. In 10 of 16 analyses, CDR3 sequences were less likely to contain an HLA binder in HLA-positive individuals; in three analyses an opposite effect was seen (Table). These results indicate that the peripheral BCR repertoire is shaped by HLA alleles in healthy individuals, most likely by T-cell mediated recognition of BCR peptides. Ongoing studies expand this fundamental finding with respect to the IC50 threshold, the number of nonamers, and additional HLA alleles. Our results warrant investigation of the potential role of HLA-dependent shaping of the BCR repertoire for the immune defense and the development of autoimmune disease and B-cell lymphoma. Table 1V(D)J without HLA binding peptideCDR3 without HLA binding peptideHLADonorμγκλμγΚλ A01*01Positive21%41%61%37%87%90%98%70%Negative16%42%59%38%92%92%96%65%P<0.001n.s.<0.01n.s.<0.001n.s.<0.01<0.001 A02*01Positive6%4%3%32%77%77%77%70%Negative4%1%2%32%75%69%78%78%P<0.001<0.001<0.01n.s.<0.01<0.001n.s.<0.001 B07*02Positive31%13%3%13%79%73%91%96%Negative27%8%2%6%79%69%90%98%P<0.001<0.01<0.01<0.001n.s.<0.05<0.05<0.001 B08*01Positive30%35%64%64%89%87%92%96%Negative14%28%62%61%88%82%90%93%P<0.001<0.001<0.01<0.001<0.01<0.001<0.01<0.001 Disclosures No relevant conflicts of interest to declare.


2006 ◽  
Vol 282 (10) ◽  
pp. 7405-7415 ◽  
Author(s):  
Catherine M. Radcliffe ◽  
James N. Arnold ◽  
David M. Suter ◽  
Mark R. Wormald ◽  
David J. Harvey ◽  
...  

2006 ◽  
Vol 281 (52) ◽  
pp. 39806-39818 ◽  
Author(s):  
Jiyuan Ke ◽  
Murali Gururajan ◽  
Anupam Kumar ◽  
Alan Simmons ◽  
Lilia Turcios ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document